Thank you for standing by, and welcome to the ResMed annual meeting. I'll now turn the call over to Mike Ryder. Thank you. Good afternoon and good morning, ladies and gentlemen. Thank you for joining us today. My name is Mike Rider, ResMed's Global General Counsel and Secretary. Welcome to ResMed's 2025 Annual Stockholders' Meeting. To provide expanded stockholder access and participation, we are once again conducting our annual meeting in a virtual-only format. During the meeting, the online polls will be open for voting by anyone who is registered on the portal and wishes to vote online with respect to any of the five proposals. Instructions for online registration can be found in your proxy materials. While the meeting is virtual-only, we welcome questions from our stockholders. We will answer questions from stockholders who have registered via the virtual meeting portal. If you're registered, you will have an opportunity to ask questions related to the proposals when each proposal is taken up. If you have difficulty registering, please email us at investorrelations@resmed.com. We have a team standing by that can help you. We will close the polls at the end of the discussion of our five proposals. We will also have a general Q&A portion of the meeting where other questions can be asked. I'd like to call your attention to the rules of conduct for the meeting. They can be found at the link located at the bottom of the virtual annual meeting screen. I will now turn the meeting over to our host, Mr. Mick Farrell. Good morning and good afternoon, ladies and gentlemen, and welcome to ResMed's Annual General Meeting. I'm Mick Farrell, the Chairman and CEO of ResMed. Before we begin, I'd like to take a moment to introduce our directors and officers who are on the line and in the room with us for our virtual meeting today. Let me start with my fellow continuing directors who are present with us here in Sydney. We have Carol Burt, who is the Chair of the Nominating and Governance Committee, and a member of our Audit Committee and a member of our Compliance, Privacy, and Quality Committee. We have Chris DeLorifus, who is Chair of our Audit Committee. We have Yann DeWitt, who is a member of our Audit Committee and Compliance, Privacy, and Quality Committee. We have Karen Drexler, who is the Chair of our Compensation and Leadership Development Committee and a member of our Nominating and Governance Committee. We also have Harjit Gill, who is Chair of our Compliance, Privacy, and Quality Committee and a member of our Compensation and Leadership Development Committee, as well as Audit Committee. We have John Hernandez, who is a member of our Compliance, Privacy, and Quality Committee that I'll call CPQ for the rest of the session here. We also have Nicole Mawar Nassar, who is our newest board member and was appointed in August of this year, who we welcome from AbbVie. Nicole is a member of our Compensation and Leadership Development Committee. We do not have present, but Rich Sulpizio, who, after years of valued contributions to the board, did not seek re-election and will retire directly after this meeting. Rich was a member of the Audit Committee and Compensation and Leadership Development Committee, as well as former Chair of our Nominating and Governance Committee, and a great mentor and friend to many of us here on the board. We also have present Desni Tan, who is a member of our Compensation and Leadership Development Committee. We also have Ron Taylor, who is our Lead Independent Director and a member of our Audit Committee, Compliance, Privacy, and Quality, or CPQ Committee, and Nominating and Governance Committee. We also have Peter Farrell, who is our Founder and Chairman Emeritus to my right here in the room. Next, let me introduce two other ResMed officers who are also present with us on the speaker's line today. We have Mike Ryder, our Global General Counsel and Corporate Secretary, and Brett Sandercock, our Chief Financial Officer, who is with me here in the room as well. Let me introduce our independent auditors, KPMG. We have Christopher Finley and Pat Britt from KPMG. That's ResMed's independent registered public accounting firm, and they are available on the speaker's line. For the administration of this meeting, Mike Ryder will act as Secretary, and Jim Alden from the American Election Services will act as the Inspector of Elections. Call to order. The 2025 Annual General Meeting of Stockholders of ResMed will now come to order. We'll begin with the formal part of the meeting, which consists of items one to five on the agenda that was circulated in the Notice of Meeting and Proxy Statement. After the formal part of the meeting, I'll give a very brief presentation and then open the line for general questions and maybe answer some of those questions as I go through the presentation that have already come in online. Thank you for those. We will announce the preliminary results of the voting before the end of the meeting and after all the items have been voted upon. I will now ask Mr. Mike Ryder to report on the mailing of the Notice of Meeting and the Notice and Access to Proxy Materials and advise if there is a quorum present so that we may begin. Mr. Farrell, the Notice of Internet Availability of Proxy Materials for the meeting was mailed on or about October 2, 2025, to all stockholders of record as of September 23, 2025. Represented at this meeting in person, online, or by proxy are 114,412,392 shares of common stock, representing approximately 78.39% of the shares outstanding and entitled to vote. Thank you, Mike. A quorum is present, and we may now carry out the official business of the meeting. The time is 10:06 A.M., and the polls are now open for the matter to be voted on today. First item of business is the election of 11 directors. The Board of Directors has nominated Carol Burt, Chris DeLorifus, Yann DeWitt, Karen Drexler, myself, Peter Farrell, Harjit Gill, John Hernandez, Nicole Mawar Nassar, Desni Tan, and Ron Taylor to serve as directors of ResMed until the 2026 annual general meeting. Because no other persons have been properly nominated in accordance with the bylaws of ResMed, the nominations are now closed. Is there any discussion with respect to the nomination of directors? No questions have been submitted. Great. The second item of business is to ratify the appointment of KPMG LLP as ResMed's independent registered public accounting firm for the fiscal year ending June 30, 2026. Is there any discussion about KPMG's appointment? No questions have been submitted. Thank you. The third item of business is to approve on an advisory basis the compensation paid to our named executive officers as disclosed in the proxy statement. Is there any discussion, or are there any questions on this topic, Mike? No questions have been submitted. Great. The fourth item of business is to approve the amendment and restatement of the ResMed 2009 Incentive Award Plan, including the increase of reserve shares and elimination of fixed term. Is there any discussion on this topic? No questions have been submitted. Thank you. The fifth and final item of business is to approve the amendment and restatement of the ResMed 2018 Employee Stock Purchase Plan, or ESPP, including an increase of reserve shares and elimination of fixed term. Is there any discussion on this final topic? No questions have been submitted. Thank you, Mike. These are the only proposals for today's meeting. The time is 10:09 A.M. Australian Eastern Daylight Time on November 20th, and the polls are now closed for this meeting. The Inspector of Elections has completed the preliminary vote tabulation, so will the Secretary of the meeting please report on those voting results? The preliminary results are as follows: Carol Burt, Chris DeLorifus, Yann DeWitt, Karen Drexler, Mick Farrell, Peter Farrell, Harjit Gill, John Hernandez, Nicole Mawar Nassar, Desni Tan, and Ron Taylor are all elected as directors. Item number two, the appointment of KPMG as our independent registered public accounting firm is ratified. Number three, the proposal to approve on an advisory basis the compensation paid to our named executive officers, as disclosed in the proxy statement, is approved. Number four, the proposal to approve the amendment and restatement of the ResMed 2009 Incentive Award Plan, including an increase of reserve shares and elimination of the fixed term, is approved. Number five, the proposal to approve the amendment and restatement of the ResMed 2018 Employee Stock Purchase Plan, including increase of reserve shares and elimination of the fixed term, is approved. The final results and voting details will be reported in a filing we will make with the United States Securities and Exchange Commission and on the Australian Stock Exchange, which will be available on our website. Thank you, Mike. This concludes the formal portion of our annual general meeting, and I declare the meeting adjourned. Now that the formal business has been transacted, I'll take just a few minutes to update you on ResMed's progress this past year, and particularly an update and restatement of our 2030 strategy that we launched exactly a year ago on our 25th anniversary on the New York Stock Exchange. We will actually now entertain any questions from shareholders during my presentation, so I ask that you go on the online portal and put those through. Some have already come in, and I'll address those as we go rather than wait till the end. Okay, we have four slides here, and so I'll go through them very briefly because everything we have said and done in the last 12 months is available on investor.resmed.com, including an incredibly detailed overview of our 2030 strategy from 10 of my top executives that's available on investor.resmed.com. Page four from the presentation here, and there's only four content pages, but page four talks about our vision, our mission, and our financial goals and key capabilities. I'll just read our vision and mission and then talk a little bit to one of the questions on the call, which was, how is artificial intelligence a tailwind for the company? I'll cover that in this slide. Our vision is that ResMed envisions a world where every person can achieve their full potential through better sleep and better breathing, with world-class healthcare delivered right in their own home. Our mission is to create life-changing and life-saving healthcare technologies that people love. In terms of our key capabilities and how we execute it, I'm going to answer this question about how AI is a tailwind for the company, not by talking about the many hundreds of experiments we're doing in artificial intelligence within our internal systems, but about products that we've launched to market. We have launched a generative AI product called Dawn, which is on our Maya platform, our portable patient app, which has about 10.8 million users. Dawn is really what I call a digital sleep health concierge or the start of that. Now those 10.8 million people can interact with a person, an entity that helps them sleep better, breathe better, helps them have more water during the day, less coffee towards the afternoon, less alcohol later, coaches them in exercise to have better breathing and better sleep at night so they have a better life. Another product we've released is the Compliance Predictor that sits on another of our digital health platforms called AirView for physicians and healthcare providers. This allows our home medical equipment customers and our physician customers to look at patients in those first 90 days and target if someone's on the verge of quitting or on the verge of staying on therapy, how they can best interact with them. It does it automated and sits on our AI platform, which is on AirView. Quickly, our financial goals, you heard this from us a year ago at the New York Stock Exchange. We said that we're going to hit high single-digit revenue growth all the way through 2030 every year. We talked about getting operating leverage so that we can hit double-digit growth on earnings per share as we go through that. Our goal, more than those financial numbers, though, is in the last 12 months, we helped 150-plus million people with a CPAP and APAP or bi-level, a mask system, or a digital health solution like myAir or AirView or Brightree or MEDIFOX DAN. We're going to grow that volume of impact every year through 2030, and we're going to improve 500 million lives. Our goal is to improve 500 million lives by 2030. Moving really quickly to slide five, this is more about our internal team, our 2030 operating model. It's simple. It's product-led, it's customer-centric, and it's brand-enhanced. How you, the shareholders, see that show up and customers see that show up is in increased product velocity. We're bringing more products to market than ever before. Our first ever-to-the-world fabric-based mask launched just a year ago, almost to the day, is the AirTouch N30i. We just launched just this quarter the AirTouch F30i, which is a fabric-based full-face mask. Customer-centric, how you see that is increased profitable growth. You've seen us increase 200-300 basis points year on year on gross margin this last 12 months. We're talking about now a productivity pipeline so we can have double-digit improvement in gross margin every year through 2030. How we use that and reinvest in the business is increasing profitable growth. Brand-enhanced, I hope you've noticed the shareholders an increase in the ResMed brand. It's worth tens of billions of dollars, and we're bringing that value to life in how consumers make decisions to choose us, physicians make decisions to prescribe us, and HMEs and many other providers and customers make the decision to use our systems because they save lives and save money. Page six, I won't cover all of you are covering this on the financial side and can see this in detail. Top-line growth trailing 12 months, double-digit, 12%. Let's jump straight to the bottom line. Non-GAAP EPS growing at 14%. Incredible growth and leverage, as you see, of 200 basis points over the trailing five-year or 60-quarter average. Page seven talks a little bit and is our final slide here to our allocation of capital. We generate a lot of cash in the last 12 months, $1.7 billion of cash. We reinvest that back in the business. The best places to reinvest is in ourselves. We put 6-7% of our revenues straight back into our technology. I'm here in the Sydney building right now. It's into the engineering, the design, the manufacturability, and getting the best, smallest, quietest, most comfortable, most cloud-connected, and most intelligent devices to market. In addition to that, we are investing in our sales and marketing. We're driving demand generation, demand ROI. It's around 19% of our revenues that go into SG&A. In addition to that, we are giving you shareholders back your money. We are increasing our dividends and have every year for a number of years. We're increasing our share repurchases. You saw us move from $100 million a quarter to $150 million a quarter. I'm here with my board of directors. We'll be talking about the opportunity to increase that as we go forward on share repurchases. There is the final use of capital, which is M&A. You saw us just in the last 12 months do some pretty interesting M&A. Bought a company called Ectosense with a fingertip-sized home sleep apnea test, the smallest sleep apnea test in the world and one of the most effective in sensitivity and specificity. That is the NightOwl. We've launched that to our US market. The other M&A I'll talk about, the final one, is a company called VirtuOx, where we bought a virtual home sleep apnea testing company that allows us to provide services for our primary care physicians, our sleep physicians, and our sleep clinics to help them efficiently diagnose sleep apnea in the home so that many more of the 77 million Americans and 1 billion people worldwide who suffocate can get access to our care. I think I've completed the presentation and answered all the questions that came up on the online system. That concludes our meeting. Thank you all for joining us today. The time is 10:17 A.M., and I will hand the call back to the operator. Thank you. This concludes today's conference call. You may now disconnect.